{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T22:46:26Z","timestamp":1787697986498,"version":"build-2784847793"},"reference-count":29,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[1999,2]]},"abstract":"<jats:p> PURPOSE: Sarcomatoid variants of renal cell carcinoma (RCC) are aggressive tumors that respond poorly to immunotherapy. We report the outcomes of 31 patients with sarcomatoid RCC treated with a combination of surgical resection and immunotherapy. <\/jats:p><jats:p> PATIENTS AND METHODS: Patients were identified from the database of the University of California Los Angeles Kidney Cancer Program. We retrospectively reviewed the cases of 31 consecutive patients in whom sarcomatoid RCC was diagnosed between 1990 and 1997. Clinical stage, sites of metastasis, pathologic stage, and type of immunotherapy were abstracted from the medical records. The primary end point analyzed was overall survival, and a multivariate analysis was performed to distinguish any factors conferring an improved survivorship. <\/jats:p><jats:p> RESULTS: Twenty-six percent of patients were male and 74% were female, and the median age was 59 years (range, 34 to 73 years). Length of follow-up ranged from 2 to 77 months (mean, 21.4 months). Twenty-eight patients (84%) had known metastases at the time of radical nephrectomy (67% had lung metastases and 40% had bone, 21% had liver, 33% had lymphatic, and 15% had brain metastases). Twenty-five patients (81%) received immunotherapy, including low-dose interleukin (IL)-2\u2013based therapy (five patients), tumor-infiltrating lymphocyte\u2013based therapy plus IL-2 (nine patients), high-dose IL-2\u2013based therapy (nine patients), dendritic cell vaccine\u2013based therapy (one patient), and interferon alpha\u2013based therapy alone (one patient). Two patients (6%) achieved complete responses (median duration, 46+ months) and five patients (15%) achieved partial responses (median duration, 36 months). One- and 2-year overall survival rates were 48% and 37%, respectively. Using a multivariate analysis, age, sex, and percentage of sarcomatoid tumor (&lt; or &gt; 50%) did not significantly correlate with survival. Improved survival was found in patients receiving high-dose IL-2 therapy compared with patients treated with surgery alone or any other form of immunotherapy (P = .025). Adjusting for age, sex, and percentage of sarcomatoid tumor, the relative risk of death was 10.4 times higher in patients not receiving high-dose IL-2 therapy. Final pathologic T stage did not correlate significantly with outcome, but node-positive patients had a higher death rate per year of follow-up than did the rest of the population (1.26 v 0.76, Cox regression analysis). <\/jats:p><jats:p> CONCLUSION: Surgical resection and high-dose IL-2\u2013based immunotherapy may play a role in the treatment of sarcomatoid RCCs in select patients. <\/jats:p>","DOI":"10.1200\/jco.1999.17.2.523","type":"journal-article","created":{"date-parts":[[2017,2,24]],"date-time":"2017-02-24T06:19:31Z","timestamp":1487917171000},"page":"523-523","source":"Crossref","is-referenced-by-count":136,"title":["Sarcomatoid Renal Cell Carcinoma: Biologic Behavior, Prognosis, and Response to Combined Surgical Resection and Immunotherapy"],"prefix":"10.1200","volume":"17","author":[{"given":"Thomas","family":"Cangiano","sequence":"first","affiliation":[{"name":"From the Department of Urology and Department of Medicine, Division of Hematology Oncology, University of California Los Angeles School of Medicine, Los Angeles, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Liao","sequence":"additional","affiliation":[{"name":"From the Department of Urology and Department of Medicine, Division of Hematology Oncology, University of California Los Angeles School of Medicine, Los Angeles, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Naitoh","sequence":"additional","affiliation":[{"name":"From the Department of Urology and Department of Medicine, Division of Hematology Oncology, University of California Los Angeles School of Medicine, Los Angeles, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick","family":"Dorey","sequence":"additional","affiliation":[{"name":"From the Department of Urology and Department of Medicine, Division of Hematology Oncology, University of California Los Angeles School of Medicine, Los Angeles, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Figlin","sequence":"additional","affiliation":[{"name":"From the Department of Urology and Department of Medicine, Division of Hematology Oncology, University of California Los Angeles School of Medicine, Los Angeles, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arie","family":"Belldegrun","sequence":"additional","affiliation":[{"name":"From the Department of Urology and Department of Medicine, Division of Hematology Oncology, University of California Los Angeles School of Medicine, Los Angeles, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"R1-0523","doi-asserted-by":"crossref","unstructured":"Landis  S,  Murray  T,  Bolden  S, et al: Cancer statistics, 1998.  CA Cancer J Clin 481:6,1998-29,","DOI":"10.3322\/canjclin.48.1.6"},{"key":"R2-0523","unstructured":"Belldegrun  A,  Abi-Aad  A,  Figlin  R, et al: Renal cell carcinoma: Basic biology and current approaches to therapy.  Semin Oncol 18:96,1991-101,  (suppl 7)"},{"key":"R3-0523","unstructured":"Mulders  P,  Figlin  R,  deKernion J,et al: Renal cell carcinoma: Recent progress and future directions.  Cancer Res 57:5189,1997-5195,"},{"key":"R4-0523","unstructured":"Franklin  JR,  Figlin  R,  Belldegrun  A: Renal cell carcinoma: Basic biology and clinical behavior.  Semin Urol Oncol 144:208,1996-215,"},{"key":"R5-0523","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(196809)22:3<556::AID-CNCR2820220310>3.0.CO;2-N"},{"key":"R6-0523","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)51388-9"},{"key":"R7-0523","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19870915)60:6<1313::AID-CNCR2820600625>3.0.CO;2-1"},{"key":"R8-0523","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19930401)71:7<2292::AID-CNCR2820710720>3.0.CO;2-3"},{"key":"R9-0523","doi-asserted-by":"publisher","DOI":"10.1159\/000475145"},{"key":"R10-0523","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(1971)28:5<1165::AID-CNCR2820280513>3.0.CO;2-G"},{"key":"R11-0523","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197311)32:5<1017::AID-CNCR2820320501>3.0.CO;2-Z"},{"key":"R12-0523","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19870201)59:3<516::AID-CNCR2820590327>3.0.CO;2-W"},{"key":"R13-0523","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19870201)59:3<527::AID-CNCR2820590328>3.0.CO;2-P"},{"key":"R14-0523","doi-asserted-by":"crossref","unstructured":"Juhasz  J,  Sebok  J,  Galambos  J, et al: Renal carcinosarcoma (mixed tumours) of the kidney.  Int Urol Nephrol 122:103,1980-108,","DOI":"10.1007\/BF02089347"},{"key":"R15-0523","doi-asserted-by":"crossref","unstructured":"Lupera  H,  Theodore  C,  Ghosn  M, et al: Phase II trial of combination chemotherapy with dacarbazine, cyclophosphamide, cisplatin, doxorubicin, and vindesine (DECAV) in advanced renal cell cancer.  Urology 345:281,1989-283,","DOI":"10.1016\/0090-4295(89)90326-9"},{"key":"R16-0523","doi-asserted-by":"crossref","unstructured":"Figlin  RA,  Pierce  WC,  Kaboo  R, et al: Treatment of metastatic renal cell carcinoma with nephrectomy, interleukin-2 and cytokine-primed or CD8(+) selected tumor infiltrating lymphocytes from primary tumor.  J Urol 158: (part 1):740,1997-745,","DOI":"10.1016\/S0022-5347(01)64304-0"},{"key":"R17-0523","unstructured":"Franklin  JR,  Figlin  R,  Rauch  J, et al: Cytoreductive surgery in the management of metastatic renal cell carcinoma: The UCLA experience.  Semin Urol Oncol 144:230,1996-236,"},{"key":"R19-0523","doi-asserted-by":"publisher","DOI":"10.1097\/00000478-198210000-00007"},{"key":"R20-0523","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1994.12.8.1572"},{"key":"R21-0523","doi-asserted-by":"crossref","unstructured":"Taneja  SS,  Pierce  W,  Figlin  R, et al: Immunotherapy for renal cell carcinoma: The era of interleukin-2-based treatment.  Urology 456:911,1995-924,","DOI":"10.1016\/S0090-4295(99)80108-3"},{"key":"R22-0523","doi-asserted-by":"crossref","unstructured":"Taneja  SS,  Pierce  W,  Figlin  R, et al: Management of disseminated kidney cancer.  Urol Clin North Am 214:625,1994-637,","DOI":"10.1016\/S0094-0143(21)00637-6"},{"key":"R23-0523","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1992.10.3.414"},{"key":"R24-0523","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1993.11.9.1809"},{"key":"R25-0523","unstructured":"Hinckel  A,  Gitlitz  B,  Mulders  P, et al: Dendritic cell (DC) therapy for metastatic renal cell cancer (MRCC): From basic research to a phase I clinical trial.  1998 Annual meeting of the American Urological Association, San Diego, CA. J Urol 159:148,1998,  (suppl)"},{"key":"R26-0523","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19830901)52:5<899::AID-CNCR2820520526>3.0.CO;2-#"},{"key":"R27-0523","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)43860-2"},{"key":"R28-0523","doi-asserted-by":"crossref","unstructured":"Belldegrun  A,  Tso  C,  Kaboo  R, et al: Natural immune reactivity\u2013associated therapeutic response in patients with metastatic renal cell carcinoma receiving tumor-infiltrating lymphocytes and interleukin-2-based therapy.  J Immunol Emphasis Tumor Immunol 192:149,1996-161,","DOI":"10.1097\/00002371-199603000-00008"},{"key":"R29-0523","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1986.03380220083027"},{"key":"R30-0523","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.3.688"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.1999.17.2.523","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T21:25:31Z","timestamp":1653513931000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.1999.17.2.523"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1999,2]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[1999,2]]}},"alternative-id":["10.1200\/JCO.1999.17.2.523"],"URL":"https:\/\/doi.org\/10.1200\/jco.1999.17.2.523","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[1999,2]]}}}